Abstract 2123P
Background
Immuno-nutritional scores like neutrophil-lymphocyte ratio (NLR), prognostic nutritional index (PNI), modified Glasgow prognostic score (mGPS) and controlling nutritional status (CONUT) have been developed to reflect the chronic inflammatory state and malnutrition induced by cancer, and to predict clinical outcomes. This study aims to investigate the prognostic value of these scores in hospitalized patients with lung cancer as we know that unscheduled admission in patients with cancer may imply organ fragility.
Methods
In this retrospective study, we examined patients with lung cancer and unscheduled hospitalizations that took place between June 2021 and May 2022 within the Medical Oncology Service of La Paz University Hospital in Madrid, Spain.
The optimal cutoff for continuous variables was evaluated with Youden index. Survival since admission was estimated with the Kaplan-Meier method. Univariate and multivariate analyses were performed by Cox regression model to determine independent prognostic factors. Areas under the curve (AUCs) or ROCs were calculated to evaluate the discriminatory ability.
Results
We admitted 158 patients with a median age of 68 years, majority of male (66.5%) and stage IV predominance (84.8%). The median follow-up was 14.9 months. The median overall survival since admission was 3.3 months (95%CI: 1.86-7.74). The optimal cut-off value for NLR was calculated to be 6 (Youden index=0.2) and for PNI was 40 (Youden index=0.1). In univariate analysis, poorer survival was associated with NLR>6 (1.87 vs 7.40 months, p=0.006, HR 1.67, 95%CI 1.16-2.42) and PNI<40 (1.67 vs 4.97 months, p=0.044, HR 1.49, 95%CI 1.01-2.20) and was not associated with CONUT (p=0.70) or mGPS (p=0.067). In the multivariate analysis only NLR>6 was an independent prognostic factor (p=0.042, HR 1.61, 95%CI 1.02-2.57). The ROC curve to evaluate the discriminatory ability of 30-day mortality was only significant in the case of NLR>6 (p=0.035, AUC 0.599, 95%CI 0.51-0.69).
Conclusions
In our setting, NLR was the most robust score for estimating prognosis in hospitalized patients with lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06